

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY AGREEMENT
CONVEYING PARTY DATA	
Name	Execution Date
Exagen Diagnostics, Inc.	10/01/2007
RECEIVING PARTY DATA	
Name:	Tullis-Dickerson Capital Focus III, L.P.
Street Address:	Two Greenwich Plaza, 4th Floor
City:	Greenwich
State/Country:	CONNECTICUT
Postal Code:	06830
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	10981277
Application Number:	11112908
Application Number:	11159799
Application Number:	11417450
Application Number:	11112926
Application Number:	11112944
CORRESPONDENCE DATA	
Fax Number:	(214)745-5390
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	jmuennink@winstead.com
Correspondent Name:	Cathryn Berryman c/o Winstead
Address Line 1:	P.O. Box 50784
Address Line 4:	Dallas, TEXAS 75250-0784
ATTORNEY DOCKET NUMBER:	46812-2
NAME OF SUBMITTER:	Cathryn Berryman

CH \$240.00 10981277

PATENT

500398611

REEL: 020111 FRAME: 0927

Total Attachments: 12

source=46812 2 updated security agreement patents#page1.tif
source=46812 2 updated security agreement patents#page2.tif
source=46812 2 updated security agreement patents#page3.tif
source=46812 2 updated security agreement patents#page4.tif
source=46812 2 updated security agreement patents#page5.tif
source=46812 2 updated security agreement patents#page6.tif
source=46812 2 updated security agreement patents#page7.tif
source=46812 2 updated security agreement patents#page8.tif
source=46812 2 updated security agreement patents#page9.tif
source=46812 2 updated security agreement patents#page10.tif
source=46812 2 updated security agreement patents#page11.tif
source=46812 2 updated security agreement patents#page12.tif

**AMENDED AND RESTATED NOTICE OF
GRANT OF SECURITY INTEREST IN PATENTS**
(Exagen Diagnostics, Inc.)

This AMENDED AND RESTATED NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS (this "Agreement"), dated as of October 1, 2007, is executed by and between Exagen Diagnostics, Inc., a Delaware corporation ("Debtor") and Tullis-Dickerson Capital Focus III, L.P., in its capacity as administrative agent ("Secured Party") pursuant to the Security Agreement described below. This Agreement amends, supersedes and replaces in its entirety the Notice of Grant of Security Interest in Patents, dated January 26, 2007, by and between the Debtor and Secured Party.

RECITALS:

WHEREAS, pursuant to the terms of that certain Amended and Restated Security Agreement, dated as of October 1, 2007, between Debtor and Secured Party (the "Security Agreement"), Debtor has granted to Secured Party, for the benefit of itself and certain lenders, a continuing lien on and security interest in all intellectual property of Debtor including, without limitation, all of Debtor's right, title and interest in, to and under all now owned and hereafter acquired patents and patent licenses, and all products and proceeds thereof.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Debtor hereby grants to Secured Party, for the benefit of itself and certain lenders, a lien on and continuing security interest in all of Debtor's right, title and interest in, to, and under the following (all of the following items or types of property being herein collectively referred to as the "Patent Collateral"), whether presently existing or hereafter created or acquired:

(a) (i) all letters patent of the United States or any other country and all reissues and extensions thereof, including, without limitation, any letters patent referred to in Schedule 1 attached hereto, and (ii) all applications for letters patent of the United States or any other country and all divisions, continuations and continuations-in-part thereof including, without limitation, any thereof referred to in Schedule 1 attached hereto (collectively, "Patents");

(b) all agreements, whether written or oral, providing for the grant by or to Debtor of any right to manufacture, use or sell any invention covered by a Patent (collectively, "Patent Licenses"); and


(c) all products and proceeds of the foregoing, including, without limitation, any claim by Debtor against third parties for past, present or future infringement or breach of any Patent or Patent License.

The lien and security interest contained in this Agreement is granted in conjunction with the security interests granted to Secured Party, for the benefit of itself and certain lenders, pursuant to the Security Agreement. Debtor hereby acknowledges and affirms that the rights and remedies of Secured Party with respect to the security interests in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

IN WITNESS WHEREOF, Debtor has caused this Agreement to be duly executed by its duly authorized officer as of the 1st day of October, 2007.

DEBTOR:

EXAGEN DIAGNOSTICS, INC.

By: 
James A. McClintic,
Chief Executive Officer

SECURED PARTY:

TULLIS-DICKERSON CAPITAL FOCUS III, L.P.

By: Tullis-Dickerson Partners III, L.L.C.,
its general partner

By: _____
Thomas P. Dickerson, Principal

IN WITNESS WHEREOF, Debtor has caused this Agreement to be duly executed by its duly authorized officer as of the 1st day of October, 2007.

DEBTOR:

EXAGEN DIAGNOSTICS, INC.

By: _____

James A. McClintic,
Chief Executive Officer

SECURED PARTY:

TULLIS-DICKERSON CAPITAL FOCUS III, L.P.

By: Tullis-Dickerson Partners III, L.L.C.,
its general partner

By: _____

Thomas P. Dickerson, Principal

Timothy M. Buono

STATE OF TEXAS)
)
COUNTY OF TRAVIS)


This instrument was acknowledged before me this 28 day of September, 2007, by James A. McClintic, Chief Executive Officer of Exagen Diagnostics, Inc., a Delaware corporation, on behalf of such entity.

Denise R. Watkins

{Seal}

Notary Public in and for the State of Texas

My commission expires: April 17, 2010



STATE OF CONNECTICUT)
)
COUNTY OF _____)

This instrument was acknowledged before me this ____ day of _____, 2007, by Thomas P. Dickerson, Principal of Tullis-Dickerson Partners III, L.L.C., the general partner of Tullis-Dickerson Capital Focus III, L.P., a Delaware limited partnership, on behalf of such entity.

{Seal}

Notary Public in and for the State of Connecticut

My commission expires: _____

STATE OF TEXAS)
)
COUNTY OF TRAVIS)

This instrument was acknowledged before me this ____ day of _____, 2007, by James A. McClintic, Chief Executive Officer of Exagen Diagnostics, Inc., a Delaware corporation, on behalf of such entity.

{Seal}

Notary Public in and for the State of Texas

My commission expires: _____

STATE OF CONNECTICUT)
)
COUNTY OF FAIRFIELD)

Timothy M. Buongiorno This instrument was acknowledged before me this 27th day of September, 2007, by ~~Thomas P. Dickerson~~, Principal of Tullis-Dickerson Partners III, L.L.C., the general partner of Tullis-Dickerson Capital Focus III, L.P., a Delaware limited partnership, on behalf of such entity.

{Seal}

Regina M. Lupo

Notary Public in and for the State of Connecticut
REGINA M. LUPO
NOTARY PUBLIC
MY COMMISSION EXPIRES 9/30/2009

My commission expires: 9/30/09

Schedule 1

See attached list.

Friday, March 02, 2007

Patent List

Page: 1

Owner: EXAG

Case Number/Subcase Country Name	Case Type	Application Number/Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
03-968/US United States of America	ORD	10/981277 03-Nov-2004	05-0181389 18-Aug-2005		Published

Client Name: Exagen Corporation
Agent Name:
Title: Compositions and Methods for Glioma Classification

Attorney(s): DSH CPS
Client Ref:
Agent Ref:

04-164/EP
European Patent Convention

PCT 05744871.4
22-Apr-2005

Published

Client Name: Exagen Corporation
Agent Name: Dr. Volker Vossius
Title: Breast Cancer Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref: 150-243

04-164/IN
India

PCT 3019/KOLNP/2006
18-Oct-2006

Pending

Client Name: Exagen Corporation
Agent Name: K & S Partners
Title: Breast Cancer Biomarkers

Attorney(s): DSH AFB
Client Ref:
Agent Ref: IP04497/GAK

PATENT

REEL: 020111 FRAME: 0936

Patent List

Friday, March 02, 2007

Owner: EXAG

Case Number/Subcase Country Name

04-164/JP
Japan

Case Type PCT
Application Number/Date 2007-506381
13-Nov-2006

Publication Number/Date

Patent Number/Date

Status Expiration Date
Pending

Attorney(s): DSH AFB
Client Ref:
Agent Ref: PF 06014

Client Name: Exagen Corporation
Agent Name: ONDA TECHNO International Patent Attorneys
Title: Breast Cancer Biomarkers

04-164/US
United States of America

ORD 11/112908
22-Apr-2005 2005-0260659
24-Nov-2005

Published

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Client Name: Exagen Corporation
Agent Name:
Title: Breast Cancer Biomarkers

04-165/US
United States of America

ORD 11/159799
23-Jun-2005 US2005-0287578
29-Dec-2005

Published

Attorney(s): DSH AFB
Client Ref:
Agent Ref:

Client Name: Exagen Corporation
Agent Name:
Title: Methods for RNA Fluorescence In Situ Hybridization

PATENT

REEL: 020111 FRAME: 0937

Friday, March 02, 2007

Patent List

Owner: EXAG

Exagen Corporation

Case Number/Subcase
Country Name

Case Type Application
Number/Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

05-116/PCT
Patent Cooperation Treaty

ORD US06/17371
03-May-2006

WO2006/119494
09-Nov-2006

Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref:

Client Name: Exagen Corporation

Agent Name:

Title: Acute Myelogenous Leukemia Biomarkers

05-116/US
United States of America

ORD 11/417450
03-May-2006

US-2006-0281107-A1
14-Dec-2006

Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref:

Client Name: Exagen Corporation

Agent Name:

Title: Acute Myelogenous Leukemia Biomarkers

05-218/PCT
Patent Cooperation Treaty

ORD US06/10195
20-Mar-2006

WO2006/104761
05-Oct-2006

Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref:

Client Name: Exagen Corporation

Agent Name:

Title: Unique Sequence Hybridization Probes

PATENT

REEL: 020111 FRAME: 0938

Patent List

Friday, March 02, 2007

Owner: EXAG

Exagen Corporation

Case Number/Subcase
Country Name

Case Type Application
Number/Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

05-218/US
United States of America

ORD 11/112926
22-Apr-2005

US-2006-0223075-A1
05-Oct-2006

Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref:

Client Name: Exagen Corporation

Agent Name:

Title: Unique Sequence Hybridization Probes

05-325/EP
European Patent Convention

PCT 05740216.6
22-Apr-2005

1737981
03-Jan-2007

Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref: 150-245

Client Name: Exagen Corporation

Agent Name: Dr. Volker Vossius

Title: Breast Cancer Gene Expression Biomarkers

05-325/JP
Japan

PCT 2007-508652
13-Oct-2006

Pending

Attorney(s): DSH AFB

Client Ref:

Agent Ref: PF 06065

Client Name: Exagen Corporation

Agent Name: ONDA TECHNO International Patent Attorneys

Title: Breast Cancer Gene Expression Biomarkers

PATENT

REEL: 020111 FRAME: 0939

Patent List

Friday, March 02, 2007
Owner: EXAG
Case Number/Subcase
Country Name
05-325/US
United States of America

Exagen Corporation

Case Type
ORD
Application Number/Date
11/112944
22-Apr-2005

Publication Number/Date
US-2005-0244872
03-Nov-2005

Status
Expiration Date
Published

Attorney(s): DSH AFB

Client Ref:

Agent Ref:

Client Name: Exagen Corporation

Agent Name:

Title: Breast Cancer Gene Expression Biomarkers

PATENT

REEL: 020111 FRAME: 0940

RECORDED: 11/14/2007